NeuroMetrix, Inc. noted presentation of new clinical data at the Diabetes UK meeting held April 23-26 in Liverpool, UK. The scientific poster was titled "Abnormal combined diabetic peripheral neuropathy (DPN)-check and SUDOSCAN results predict all-cause mortality in people with diabetes: The Sheffield prospective study." The study prospectively followed 245 individuals with diabetes for 7-years following screening for peripheral neuropathy. The screening tests included a structured clinical exam (Toronto Clinical Neuropathy Score, TCNS), the Semmes-Weinstein Monofilament test (10 g-MFT) that is a subjective, clinical test for DPN, a device (Sudoscan®?) that measures autonomic nerve function, and DPNCheck.

DPNCheck and Sudoscan are complementary validated point-of-care tests for DPN. The initial cross-sections screening results were previously published and showed that DPNCheck was the most accurate individual test for DPN. As reported in the Diabetes UK poster, after adjusting for age, HbA1c and total cholesterol, only abnormal results from DPNCheck and Sudos can were significantly associated with all-cause mortality (HR=1.18, p=0.04) after 7-years.